These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11401299)

  • 1. High-throughput fluorogenic assay for determination of botulinum type B neurotoxin protease activity.
    Anne C; Cornille F; Lenoir C; Roques BP
    Anal Biochem; 2001 Apr; 291(2):253-61. PubMed ID: 11401299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial protection against Botulinum B neurotoxin-induced blocking of exocytosis by a potent inhibitor of its metallopeptidase activity.
    Anne C; Turcaud S; Blommaert AG; Darchen F; Johnson EA; Roques BP
    Chembiochem; 2005 Aug; 6(8):1375-80. PubMed ID: 15988765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide substrate specificity and properties of the zinc-endopeptidase activity of botulinum type B neurotoxin.
    Shone CC; Roberts AK
    Eur J Biochem; 1994 Oct; 225(1):263-70. PubMed ID: 7925446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin.
    Schiavo G; Shone CC; Rossetto O; Alexander FC; Montecucco C
    J Biol Chem; 1993 Jun; 268(16):11516-9. PubMed ID: 8505288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production of an expression system for a synaptobrevin fragment to monitor cleavage by botulinum neurotoxin B.
    Nowakowski JL; Courtney BC; Bing QA; Adler M
    J Protein Chem; 1998 Jul; 17(5):453-62. PubMed ID: 9717740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the amino acid residues rendering TI-VAMP insensitive toward botulinum neurotoxin B.
    Sikorra S; Henke T; Swaminathan S; Galli T; Binz T
    J Mol Biol; 2006 Mar; 357(2):574-82. PubMed ID: 16430921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzymatic profiling of tetanus and botulinum neurotoxins based on vesicle-associated-membrane protein derived fluorogenic substrates.
    Perpetuo EA; Juliano L; Juliano MA; Fratelli F; Prado SM; Pimenta DC; Lebrun I
    Protein Pept Lett; 2008; 15(10):1100-6. PubMed ID: 19075822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tetanus and botulinum toxins are zinc metallopeptidases: molecular mechanisms and inhibition of their neurotoxicity].
    Cornille F; Roques BP
    J Soc Biol; 1999; 193(6):509-16. PubMed ID: 10783709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small tripeptide surrogates with low nanomolar affinity as potent inhibitors of the botulinum neurotoxin B metallo-proteolytic activity.
    Blommaert A; Turcaud S; Anne C; Roques BP
    Bioorg Med Chem; 2004 Jun; 12(11):3055-62. PubMed ID: 15142564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Structure and function of botulinum toxin].
    Fujii N
    Hokkaido Igaku Zasshi; 1995 Jan; 70(1):19-28. PubMed ID: 7744367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thio-derived disulfides as potent inhibitors of botulinum neurotoxin type B: implications for zinc interaction.
    Anne C; Blommaert A; Turcaud S; Martin AS; Meudal H; Roques BP
    Bioorg Med Chem; 2003 Oct; 11(21):4655-60. PubMed ID: 14527562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity.
    Adler M; Nicholson JD; Cornille F; Hackley BE
    FEBS Lett; 1998 Jun; 429(3):234-8. PubMed ID: 9662424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection and quantification of botulinum neurotoxin type a by a novel rapid in vitro fluorimetric assay.
    Poras H; Ouimet T; Orng SV; Fournié-Zaluski MC; Popoff MR; Roques BP
    Appl Environ Microbiol; 2009 Jul; 75(13):4382-90. PubMed ID: 19429547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of potent inhibitors of botulinum neurotoxin type B.
    Anne C; Turcaud S; Quancard J; Teffo F; Meudal H; Fournié-Zaluski MC; Roques BP
    J Med Chem; 2003 Oct; 46(22):4648-56. PubMed ID: 14561084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of phosphoramidon and three synthetic phosphonates for inhibition of botulinum neurotoxin B catalytic activity.
    Adler M; Nicholson JD; Starks DF; Kane CT; Cornille F; Hackley BE
    J Appl Toxicol; 1999 Dec; 19 Suppl 1():S5-S11. PubMed ID: 10594892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A capillary electrophoresis method to assay catalytic activity of botulinum neurotoxin serotypes: implications for substrate specificity.
    Purcell AL; Hoard-Fruchey HM
    Anal Biochem; 2007 Jul; 366(2):207-17. PubMed ID: 17548044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetanus and botulism neurotoxins: a new group of zinc proteases.
    Montecucco C; Schiavo G
    Trends Biochem Sci; 1993 Sep; 18(9):324-7. PubMed ID: 7901925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25.
    Blasi J; Chapman ER; Link E; Binz T; Yamasaki S; De Camilli P; Südhof TC; Niemann H; Jahn R
    Nature; 1993 Sep; 365(6442):160-3. PubMed ID: 8103915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clostridium botulinum and botulinum neurotoxin].
    Hirai Y
    Brain Nerve; 2011 Jul; 63(7):755-61. PubMed ID: 21747146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity.
    Schmidt JJ; Stafford RG
    Biochemistry; 2005 Mar; 44(10):4067-73. PubMed ID: 15751983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.